1.08
0.93%
+0.01
OptiNose Inc stock is currently priced at $1.08, with a 24-hour trading volume of 489.85K.
It has seen a +0.93% increased in the last 24 hours and a +31.55% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.07 pivot point. If it approaches the $1.09 resistance level, significant changes may occur.
Previous Close:
$1.07
Open:
$1.09
24h Volume:
489.85K
Market Cap:
$122.08M
Revenue:
$70.99M
Net Income/Loss:
$-35.48M
P/E Ratio:
-2.16
EPS:
-0.5
Net Cash Flow:
$-20.86M
1W Performance:
-2.70%
1M Performance:
+31.55%
6M Performance:
-13.60%
1Y Performance:
-13.60%
OptiNose Inc Stock (OPTN) Company Profile
Name
OptiNose Inc
Sector
Phone
267-364-3500
Address
1020 Stony Hill Road, Suite 300, Yardley, PA
OptiNose Inc Stock (OPTN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-21-22 | Resumed | Jefferies | Buy |
Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
Dec-18-19 | Initiated | Cowen | Outperform |
Aug-08-18 | Initiated | Cantor Fitzgerald | Overweight |
OptiNose Inc Stock (OPTN) Latest News
Hogan Lovells represents Optinose in its US$55 million registered direct offering - Legal Desire News Network
Legal Desire News Network
OptiNose Inc (OPTN) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
The InvestChronicle
Hogan Lovells represents Optinose in its US$55 million registered direct offering - Legal Desire News Network
Legal Desire News Network
Optinose Inc's $55 Million Common Stock Offering – Global Legal Chronicle - Global Legal Chronicle
Global Legal Chronicle
A History of Outperforming Analyst Forecasts and Beating the Odds: OptiNose Inc (OPTN) – Sete News - SETE News
SETE News
H.C. Wainwright analysts initates a Buy rating for OptiNose Inc (OPTN) – Knox Daily - Knox Daily
Knox Daily
OptiNose Inc Stock (OPTN) Financials Data
OptiNose Inc (OPTN) Revenue 2024
OPTN reported a revenue (TTM) of $70.99 million for the quarter ending December 31, 2023, a -6.93% decline year-over-year.
OptiNose Inc (OPTN) Net Income 2024
OPTN net income (TTM) was -$35.48 million for the quarter ending December 31, 2023, a +52.59% increase year-over-year.
OptiNose Inc (OPTN) Cash Flow 2024
OPTN recorded a free cash flow (TTM) of -$20.86 million for the quarter ending December 31, 2023, a +69.19% increase year-over-year.
OptiNose Inc (OPTN) Earnings per Share 2024
OPTN earnings per share (TTM) was -$0.32 for the quarter ending December 31, 2023, a +64.04% growth year-over-year.
OptiNose Inc Stock (OPTN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Marino Michael F III | Chief Legal Officer & Corp Sec |
Mar 18 '24 |
Sale |
1.88 |
15,059 |
28,311 |
602,268 |
Krick Anthony J | Chief Accounting Officer |
Mar 18 '24 |
Sale |
1.88 |
2,345 |
4,409 |
143,988 |
Mahmoud Ramy A | Chief Executive Officer |
Jan 31 '24 |
Sale |
1.31 |
52,875 |
69,266 |
548,387 |
Mahmoud Ramy A | Chief Executive Officer |
Dec 18 '23 |
Sale |
1.15 |
11,114 |
12,781 |
509,728 |
Marino Michael F III | Chief Legal Officer & Corp Sec |
Dec 18 '23 |
Sale |
1.15 |
5,005 |
5,756 |
333,511 |
Mahmoud Ramy A | Chief Executive Officer |
Sep 18 '23 |
Sale |
1.37 |
11,083 |
15,184 |
514,729 |
Marino Michael F III | Chief Legal Officer & Corp Sec |
Sep 18 '23 |
Sale |
1.37 |
4,991 |
6,838 |
334,699 |
Mahmoud Ramy A | Chief Executive Officer |
Jun 16 '23 |
Sale |
1.15 |
3,543 |
4,074 |
519,699 |
Marino Michael F III | Chief Legal Officer & Corp Sec |
Jun 16 '23 |
Sale |
1.15 |
1,516 |
1,743 |
335,873 |
About OptiNose Inc
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder; and OPN-021 for the treatment of narcolepsy or Parkinson diseases. Further, it is involved in developing antibiotics, anticholinergics, antihistamines, mucolytics, leukotriene inhibitors, and other medication classes. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.
Cap:
|
Volume (24h):